https://www.transceleratebiopharmainc.com/wp-content/uploads/2020/10/Lung-Cancer-Linnea-Olson-Patient-Story_1.mp4 Preclinical research and collaboration have historically been conducted in silos. When BioCelerate was established in 2016, our goal was to bring together sponsors to identify ways to collaborate on developing solutions that aim to improve efficiencies in preclinical research. BioCelerate has made tremendous strides in the past seven years—from developing a toxicology and background…
READ MORE
https://www.transceleratebiopharmainc.com/wp-content/uploads/2020/10/Lung-Cancer-Linnea-Olson-Patient-Story_1.mp4 This is the first post in an ongoing blog series about TransCelerate’s efforts to help biopharma R&D organizations navigate global regulations and improve safety for medications prescribed to pregnant and breastfeeding individuals. Future topics in this series will include tips on cultural shifts within an organization, patient experience in clinical trials, and future TransCelerate…
READ MORE
https://www.transceleratebiopharmainc.com/wp-content/uploads/2020/10/Lung-Cancer-Linnea-Olson-Patient-Story_1.mp4 TransCelerate, along with hundreds of sponsors, sites, Health Authorities, technology vendors, and other leaders in the biopharma R&D industry, assembled in Boston last week to attend DIA Global 2023. This year’s theme was “Illuminate,” and TransCelerate did its part by spotlighting our insights and solutions during nine sessions at this year’s event. Patients Front…
READ MORE
